[go: up one dir, main page]

WO2008071667A1 - Nutritional composition - Google Patents

Nutritional composition Download PDF

Info

Publication number
WO2008071667A1
WO2008071667A1 PCT/EP2007/063622 EP2007063622W WO2008071667A1 WO 2008071667 A1 WO2008071667 A1 WO 2008071667A1 EP 2007063622 W EP2007063622 W EP 2007063622W WO 2008071667 A1 WO2008071667 A1 WO 2008071667A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
nutritional composition
source
kcal
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/063622
Other languages
French (fr)
Inventor
Ferdinand Haschke
Corinne Magliola
Philippe Steenhout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37907402&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008071667(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US12/519,043 priority Critical patent/US9943097B2/en
Priority to PL07857342T priority patent/PL2096941T3/en
Priority to ES07857342T priority patent/ES2379737T3/en
Priority to BRPI0721087-6A priority patent/BRPI0721087A2/en
Priority to AT07857342T priority patent/ATE543395T1/en
Application filed by Nestec SA filed Critical Nestec SA
Priority to MX2009006086A priority patent/MX2009006086A/en
Priority to AU2007331578A priority patent/AU2007331578B2/en
Priority to CA002671988A priority patent/CA2671988A1/en
Priority to EP07857342A priority patent/EP2096941B1/en
Publication of WO2008071667A1 publication Critical patent/WO2008071667A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/19Dairy proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This invention relates to a nutritional composition, more specifically to a nutritional composition designed for infants deemed to be at risk of developing obesity later in life.
  • BMI body mass index
  • the present invention provides a nutritional composition for infants at risk of developing obesity later in life comprising a protein source, a lipid source and a carbohydrate source and having a protein content of less than 1.8g/100 kcal and an energy density of less than 650 kcal/litre.
  • the invention also extends to the use of a protein source, a lipid source and a carbohydrate source for the preparation of a nutritional composition having a protein content of less than 1.8g/l 00 kcal and an energy density of less than 650 kcal/litre for administration to an infant at risk of developing obesity later in life in the first year of life of the infant so as to reduce that risk.
  • the invention further extends to a method of reducing the possibility that an infant at risk of developing obesity later in life will develop obesity comprising feeding to the at risk infant in the first year of its life a nutritional composition comprising a protein source, a lipid source and a carbohydrate source and having a protein content of less than 1.8g/100 kcal and an energy density of less than 650 kcal/litre.
  • At least 20% by weight of the protein source is casein, more preferably at least 30%.
  • the ratio of linoleic acid (C18:2n-6): ⁇ -linolenic acid (C18:3n-3) in the lipid source is less than 7: 1.
  • the ratio of arachidonic acid (C20:4n- 6):docosahexaenoic acid (C22:6n-3) in the lipid source is preferably between 2:1 and
  • infant means a child under the age of 12 months
  • infant at risk of developing obesity later in life means an infant born to an obese mother
  • protein content means total content of proteinaceous material including free amino acids (if present).
  • references to the energy density of the nutritional composition in a specified number of kilocalories per litre refer, in the context of powdered products, to the product after re- constitution according to the directions provided with the product.
  • the energy density of a nutritional composition according to the invention is less than 650 kcal/1, preferably between 620 and 640 kcal/1.
  • the nutritional composition of the present invention has a protein content of less than 1.8 g/100 kcal.
  • the protein content is between 1.4 and 1.7 g/100 kcal.
  • the detailed make-up of the protein source is not believed to be critical to the present invention provided that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured.
  • protein sources based on cows' milk proteins such as whey, casein and mixtures thereof may be used as well as protein sources based on soy.
  • mixtures of whey and casein proteins are preferred.
  • the casein:whey ratio may lie in the range from 70:30 to 30:70 but is preferably 40:60.
  • the protein(s) in the protein source may be intact or partially hydrolysed or a mixture of intact and hydrolysed proteins may be used. However, intact proteins are preferred.
  • the protein source may additionally be supplemented with free amino acids if this is necessary to meet the minimum requirements for essential amino acid content. These requirements are published for example in EC Directive 91/321 /EEC. However, it will be appreciated that because of the over-riding need to control the protein content of the nutritional composition as discussed above, supplementation with free amino acids may be driven primarily by the amino acid profile of the protein source(s) selected and the resultant need to supplement with certain free amino acids if any. This is illustrated further in the examples below.
  • the preferred protein source is a mixture of casein and whey proteins.
  • the whey protein may be a whey protein isolate, acid whey, sweet whey or sweet whey from which the caseino-glycomacropeptide has been removed (modified sweet whey).
  • the whey protein is modified sweet whey.
  • Sweet whey is a readily available by-product of cheese making and is frequently used in the manufacture of nutritional compositions based on cows' milk.
  • sweet whey includes a component which is undesirably rich in threonine and poor in tryptophan called caseino- glycomacropeptide (CGMP). Removal of the CGMP from sweet whey results in a protein with a threonine content closer to that of human milk.
  • a process for removing CGMP from sweet whey is described in EP 880902.
  • modified sweet whey is used as the whey protein in a mixture of 60% whey and 40% casein
  • the protein source is preferably supplemented by free tryptophan, isoleucine, histidine and phenylalanine in amounts of up to 0.34% for tryptophan, 0.92% for isoleucine, 0.19% for histidine and 2.2% for phenylalanine (in each case as a percentage by weight of total protein content).
  • the protein source is preferably supplemented by free tryptophan, leucine, histidine and phenylalanine in amounts of up to 0.5% for tryptophan, 0.37% for leucine, 0.3% for histidine and 2.5% for phenylalanine (in each case as a percentage by weight of total protein content).
  • the nutritional compositions of the present invention contains a source of carbohydrates.
  • the preferred source of carbohydrates is lactose although other carbohydrates such as saccharose, maltodextrin, and starch may also be added.
  • the carbohydrate content of the nutritional composition is between 9 and 14 g/100 kcal.
  • the nutritional composition of the present invention contains a source of lipids.
  • the lipid source may be any lipid or fat which is suitable for use in nutritional compositions to be fed to infants.
  • Preferred fat sources include coconut oil, low erucic rapeseed oil (canola oil), soy lecithin, palm olein, and sunflower oil.
  • the essential polyunsaturated fatty acids linoleic acid and ⁇ -linolenic acid will also be added as may small amounts of oils containing high quantities of preformed long chain polyunsaturated fatty acids arachidonic acid and docosahexaenoic acid such as fish oils or single cell oils.
  • the lipid content may be between 4.4 and 6 g/100 kcal.
  • the ratio of linoleic acid (C 18:2n-6): ⁇ -linolenic acid (C18:3n-3)in the lipid source is less than 7:1, more preferably between 7:1 and 5:1.
  • the ratio of arachidonic acid (C20:4n- 6):docosahexaenoic acid (C22:6n-3) in the lipid source is preferably between 2:1 and
  • the nutritional composition may also contain all vitamins and minerals understood to be essential in the daily diet in nutritionally significant amounts. Minimum requirements have been established for certain vitamins and minerals. Examples of minerals, vitamins and other nutrients optionally present in the nutritional composition include vitamin A, vitamin Bi, vitamin B 2 , vitamin B 6 , vitamin B 12 , vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are usually added in salt form.
  • the nutritional composition may contain emulsif ⁇ ers and stabilisers such as soy lecithin, citric acid esters of mono- and di-glycerides, and the like. This is especially the case if the composition is provided in liquid form.
  • the nutritional composition may optionally contain other substances which may have a beneficial effect such as probiotic bacteria, fibres, lactoferrin, nucleotides, nucleosides, and the like in the amounts customarily found in nutritional compositions to be fed to infants.
  • the nutritional composition may be prepared in any suitable manner.
  • a nutritional composition may be prepared by blending together the protein source, the carbohydrate source, and the lipid source in appropriate proportions. If used, emulsif ⁇ ers may be included in the blend at this stage. The vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the fat source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture.
  • the liquid mixture may then be thermally treated to reduce bacterial loads.
  • the liquid mixture may be rapidly heated to a temperature in the range of about 80 0 C to about 110 0 C for about 5 seconds to about 5 minutes. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.
  • the liquid mixture may then be cooled to about 60 0 C to about 85°C; for example by flash cooling.
  • the liquid mixture may then be homogenised; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage.
  • the homogenised mixture may then be further cooled and any heat sensitive components; such as vitamins and minerals may be added.
  • the pH and solids content of the homogenised mixture is conveniently standardised at this point.
  • the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • the powder should have a moisture content of less than about 5% by weight.
  • the homogenised mixture is filled into suitable containers; preferably aseptically.
  • the liquid composition may also be retorted in the container. Suitable apparatus for carrying out filling of this nature is commercially available.
  • the liquid composition may be in the form of a ready to feed composition having a solids content of about 10 to about 14% by weight or may be in the form of a concentrate; usually of solids content of about 20 to about 26% by weight.
  • composition of a nutritional composition according to the invention is given below:
  • a nutritional composition according to the invention may be fed to an infant at risk of developing obesity later in life as the sole source of nutrition from the age of three months and subsequently as part of a mixed diet during the introduction of solid foods until weaning is complete at about the age of 12 months.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dairy Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A nutritional composition for infants at risk of developing obesity later in life comprises a protein source, a lipid source and a carbohydrate source and has a protein content of less than 1.8g/100 kcal and an energy density of less than 650 kcal/litre.

Description

Nutritional Composition
This invention relates to a nutritional composition, more specifically to a nutritional composition designed for infants deemed to be at risk of developing obesity later in life.
Mother's milk is recommended for all infants. However, in some cases breast feeding is inadequate or unsuccessful or inadvisable for medical reasons or the mother chooses not to breast feed either at all or for a period of more than a few weeks. Infant formulas have been developed for these situations.
The prevalence of obesity and overweight in adults, children and adolescents has increased rapidly over the past 30 years in the United States and globally and continues to rise. Overweight and obesity are classically defined based on the percentage of body fat or, more recently, the body mass index or BMI. The BMI is defined as the ratio of weight in Kg divided by the height in metres, squared. As overweight and obesity become more prevalent in all age groups, it is inevitable that the number of women giving birth who are also overweight or obese will increase. It is known that overweight and obese women who become pregnant have a greater risk of developing gestational diabetes. Maternal hyperglycaemia may lead to infants with increased body size and fat mass and such infants are themselves prone to develop obesity and diabetes later in childhood or in adult life. Moreover, recent research has suggested that obese women who themselves ha\e normal glucose tolerance give birth to infants with a higher fat mass than those born to women who are not obese.
An increasing weight of scientific evidence suggests that infants born to overweight and obese mothers have a greater risk of becoming overweight or obese later in life than infants born to mothers who are not overweight or obese. This predisposition appears to be higher if both parents are affected. Childhood overweight and obesity currently affects 18 million children under age 5 worldwide. Almost 30% of US children and adolescents and between 10 and 30% of European children are overweight or obese.
There is, therefore, clearly a need for a nutritional composition specifically designed to address the nutritional needs of these at risk infants whilst reducing their risk of developing obesity later in life. Summary of the Invention
Accordingly, the present invention provides a nutritional composition for infants at risk of developing obesity later in life comprising a protein source, a lipid source and a carbohydrate source and having a protein content of less than 1.8g/100 kcal and an energy density of less than 650 kcal/litre.
The invention also extends to the use of a protein source, a lipid source and a carbohydrate source for the preparation of a nutritional composition having a protein content of less than 1.8g/l 00 kcal and an energy density of less than 650 kcal/litre for administration to an infant at risk of developing obesity later in life in the first year of life of the infant so as to reduce that risk.
The invention further extends to a method of reducing the possibility that an infant at risk of developing obesity later in life will develop obesity comprising feeding to the at risk infant in the first year of its life a nutritional composition comprising a protein source, a lipid source and a carbohydrate source and having a protein content of less than 1.8g/100 kcal and an energy density of less than 650 kcal/litre.
Preferably at least 20% by weight of the protein source is casein, more preferably at least 30%.
Preferably, the ratio of linoleic acid (C18:2n-6): α-linolenic acid (C18:3n-3) in the lipid source is less than 7: 1. Further, the ratio of arachidonic acid (C20:4n- 6):docosahexaenoic acid (C22:6n-3) in the lipid source is preferably between 2:1 and
1.1.
Although obesity in childhood and adolescence is certainly increasing to the point where it is starting to be a cause of serious concern to healthcare professionals, there are clearly many contributory factors, nutritional, environmental and inherited. It is recognized that the likelihood of developing a nutritional product which is effective in reducing this risk in the infant population at large is remote. However, in the specific case of infants born to overweight and obese mothers, the present inventors believe that it may be possible to reduce the risk of future obesity by feeding the at risk infant from the age of about three months with a nutritional composition according to the invention. In other words, it is thought that feeding the at risk infant with a nutritional composition according to the invention from the age of about three months will result in the growth rate of the infant more closely approximating to the normal growth rate of a breast fed infant of the same age.
As research into the composition of human milk continues, increasing attention is being paid to the extent to which its composition changes over the period of lactation. These changes are particularly pronounced as regards protein quality and quantity. Dietary protein provides the essential amino acids necessary for protein synthesis and growth. Nutritional compositions to be fed to infants are usually based on cows' milk but the amino acid profile of cows' milk is noticeably different from that of human milk which, in addition, has the lowest protein concentration found in any mammalian milk. In the past, in order to supply enough of the essential amino acids, infant formulas based on cows' milk had to have a protein content significantly higher than that of the human milk. More recently, it has been realised that total protein quantity can be reduced whilst still meeting the minimum requirements for essential amino acids by a judicious selection of protein sources supplemented if necessary by small quantities of free amino acids.
However, this line of development does not take account of the physiological properties of particular proteins and the evolution of protein content of human milk over time. Human milk is generally considered to be whey predominant and a range of "whey- adapted'" formulas have been developed based on this. However, this fails to take account of the fact that the casein: whey ratio of human milk varies over time from 20:80 in the first few days of lactation to 50:50 after five to six months of lactation. Furthermore, the protein content of human milk is likewise not constant over time and may vary between 1.8 and 1.3g/100kcal depending upon the duration of lactation.
Without wishing to be bound by theory, the inventors believe that for infants at risk of developing obesity in particular, feeding a nutritional composition with a controlled protein and energy content which is moreover preferably relatively rich in the satiety- inducing protein casein could counteract any tendency on the part of the infant to overfeed, particularly as regards protein intake, whilst supplying sufficient quantities of nutrients essential for growth and development and resulting in a growth pattern similar to that observed in breast fed infants. Detailed Description of the Invention
In this specification, the following expressions have the meanings assigned to them below:-
"infant" means a child under the age of 12 months;
"infant at risk of developing obesity later in life" means an infant born to an obese mother
"'normal growth rate of a breast fed infant" means the growth rates for breast fed infants set out in Acta Paediatrica, VoI 95, April 2006, Supplement 450 "WHO Child Growth Standards"
"'obese mother" meεins a woman with a BMI greater than 30 prior to establishment of pregnancy;
"Overweight mother" means a woman with a BMI greater than 25 prior to establishment of pregnancy;
'"protein content" means total content of proteinaceous material including free amino acids (if present).
All percentages and ratios are by weight unless otherwise specified.
References to the energy density of the nutritional composition in a specified number of kilocalories per litre refer, in the context of powdered products, to the product after re- constitution according to the directions provided with the product.
The energy density of a nutritional composition according to the invention is less than 650 kcal/1, preferably between 620 and 640 kcal/1.
The nutritional composition of the present invention has a protein content of less than 1.8 g/100 kcal. Preferably the protein content is between 1.4 and 1.7 g/100 kcal. The detailed make-up of the protein source is not believed to be critical to the present invention provided that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured. Thus, protein sources based on cows' milk proteins such as whey, casein and mixtures thereof may be used as well as protein sources based on soy. However, mixtures of whey and casein proteins are preferred. The casein:whey ratio may lie in the range from 70:30 to 30:70 but is preferably 40:60.
The protein(s) in the protein source may be intact or partially hydrolysed or a mixture of intact and hydrolysed proteins may be used. However, intact proteins are preferred.
The protein source may additionally be supplemented with free amino acids if this is necessary to meet the minimum requirements for essential amino acid content. These requirements are published for example in EC Directive 91/321 /EEC. However, it will be appreciated that because of the over-riding need to control the protein content of the nutritional composition as discussed above, supplementation with free amino acids may be driven primarily by the amino acid profile of the protein source(s) selected and the resultant need to supplement with certain free amino acids if any. This is illustrated further in the examples below.
As noted above, the preferred protein source is a mixture of casein and whey proteins. The whey protein may be a whey protein isolate, acid whey, sweet whey or sweet whey from which the caseino-glycomacropeptide has been removed (modified sweet whey). Preferably, however, the whey protein is modified sweet whey. Sweet whey is a readily available by-product of cheese making and is frequently used in the manufacture of nutritional compositions based on cows' milk. However, sweet whey includes a component which is undesirably rich in threonine and poor in tryptophan called caseino- glycomacropeptide (CGMP). Removal of the CGMP from sweet whey results in a protein with a threonine content closer to that of human milk. A process for removing CGMP from sweet whey is described in EP 880902.
If modified sweet whey is used as the whey protein in a mixture of 60% whey and 40% casein, the protein source is preferably supplemented by free tryptophan, isoleucine, histidine and phenylalanine in amounts of up to 0.34% for tryptophan, 0.92% for isoleucine, 0.19% for histidine and 2.2% for phenylalanine (in each case as a percentage by weight of total protein content). If intact sweet whey is used as the whey protein in a mixture of 60% whey and 40% casein, the protein source is preferably supplemented by free tryptophan, leucine, histidine and phenylalanine in amounts of up to 0.5% for tryptophan, 0.37% for leucine, 0.3% for histidine and 2.5% for phenylalanine (in each case as a percentage by weight of total protein content).
The nutritional compositions of the present invention contains a source of carbohydrates. The preferred source of carbohydrates is lactose although other carbohydrates such as saccharose, maltodextrin, and starch may also be added. Preferably, the carbohydrate content of the nutritional composition is between 9 and 14 g/100 kcal.
The nutritional composition of the present invention contains a source of lipids. The lipid source may be any lipid or fat which is suitable for use in nutritional compositions to be fed to infants. Preferred fat sources include coconut oil, low erucic rapeseed oil (canola oil), soy lecithin, palm olein, and sunflower oil. The essential polyunsaturated fatty acids linoleic acid and α-linolenic acid will also be added as may small amounts of oils containing high quantities of preformed long chain polyunsaturated fatty acids arachidonic acid and docosahexaenoic acid such as fish oils or single cell oils. In total, the lipid content may be between 4.4 and 6 g/100 kcal. Preferably, the ratio of linoleic acid (C 18:2n-6): α-linolenic acid (C18:3n-3)in the lipid source is less than 7:1, more preferably between 7:1 and 5:1. Further, the ratio of arachidonic acid (C20:4n- 6):docosahexaenoic acid (C22:6n-3) in the lipid source is preferably between 2:1 and
The nutritional composition may also contain all vitamins and minerals understood to be essential in the daily diet in nutritionally significant amounts. Minimum requirements have been established for certain vitamins and minerals. Examples of minerals, vitamins and other nutrients optionally present in the nutritional composition include vitamin A, vitamin Bi, vitamin B2, vitamin B6, vitamin B12, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are usually added in salt form.
If necessary, the nutritional composition may contain emulsifϊers and stabilisers such as soy lecithin, citric acid esters of mono- and di-glycerides, and the like. This is especially the case if the composition is provided in liquid form. The nutritional composition may optionally contain other substances which may have a beneficial effect such as probiotic bacteria, fibres, lactoferrin, nucleotides, nucleosides, and the like in the amounts customarily found in nutritional compositions to be fed to infants.
The nutritional composition may be prepared in any suitable manner. For example, a nutritional composition may be prepared by blending together the protein source, the carbohydrate source, and the lipid source in appropriate proportions. If used, emulsifϊers may be included in the blend at this stage. The vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the fat source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture.
The liquid mixture may then be thermally treated to reduce bacterial loads. For example, the liquid mixture may be rapidly heated to a temperature in the range of about 800C to about 1100C for about 5 seconds to about 5 minutes. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.
The liquid mixture may then be cooled to about 600C to about 85°C; for example by flash cooling. The liquid mixture may then be homogenised; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage. The homogenised mixture may then be further cooled and any heat sensitive components; such as vitamins and minerals may be added. The pH and solids content of the homogenised mixture is conveniently standardised at this point.
If it is desired to produce a powdered composition, the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder. The powder should have a moisture content of less than about 5% by weight.
If it is desired to produce a liquid composition, the homogenised mixture is filled into suitable containers; preferably aseptically. However, the liquid composition may also be retorted in the container. Suitable apparatus for carrying out filling of this nature is commercially available. The liquid composition may be in the form of a ready to feed composition having a solids content of about 10 to about 14% by weight or may be in the form of a concentrate; usually of solids content of about 20 to about 26% by weight.
An example of the composition of a nutritional composition according to the invention is given below:-
Figure imgf000009_0001
Figure imgf000010_0001
A nutritional composition according to the invention may be fed to an infant at risk of developing obesity later in life as the sole source of nutrition from the age of three months and subsequently as part of a mixed diet during the introduction of solid foods until weaning is complete at about the age of 12 months.

Claims

Claims
1. A nutritional composition for infants at risk of developing obesity later in life comprising a protein source which includes at least 20% by weight casein, a lipid source and a carbohydrate source and having a protein content of less than
1.8g/100 kcal and an energy density of less than 650 kcal/litre.
2. A nutritional composition according to Claim 1, wherein the energy density is between 620 and 640 kcal/litre.
3. A nutritional composition according to Claim 1 or 2, wherein the protein content is between 1.4 and 1.7 g/100 kcal.
4. A nutritional composition as claimed in any preceding claim, wherein the protein source additionally includes whey protein.
5. A nutritional composition as claimed in any preceding claim, wherein the casein.'whey ratio is between 30:70 and 70:30.
6. A nutritional composition as claimed in Claim 4 or 5, wherein the whey protein is sweet whey from which the caseino-glycomacropeptide has been removed and the composition additionally includes free phenylalanine in an amount of up to 2.2%, free isoleucine in an amount of up to 0.92%, free tryptophan in an amount of up to 0.34% and free histidine in an amount of up to 0.19%, in each as a percentage by weight of total protein content.
7. A nutritional composition as claimed in any preceding claim, wherein the protein(s) are intact.
8. A nutritional composition as claimed in any preceding claim, wherein the carbohydrate source is lactose.
9. A nutritional composition as claimed in any preceding claim, wherein the ratio of linoleic acid (C18:2n-6): α-linolenic acid (C18:3n-3)in the lipid source is between 7: 1 and 5: 1.
K). A nutritional composition as claimed in any preceding claim, wherein the ratio of arachidonic acid (C20:4n-6):docosahexaenoic acid (C22:6n-3) in the lipid source is between 2:1 and 1.1
1 1 . A nutritional composition as claimed in any preceding claim, which further includes a probiotic bacterial strain in an amount of from 106 to 1011 cfu/g of composition (dry weight).
12. Use of a protein source which includes at least 20% by weight casein, a lipid source and a carbohydrate source for the preparation of a nutritional composition having a protein content of less than 1.8g/100 kcal and an energy density of less than 0.65 kcal/litre for administration to an infant at risk of developing obesity later in life in the first year of life of the infant so as to reduce that risk.
H. Use of a protein source, a lipid source and a carbohydrate source for the preparation of a nutritional composition having a protein content of less than 1 .8g/100 kcal and an energy density of less than 0.65 kcal/litre for administration to an infant at risk of developing obesity later in life in the first year of life of the infant so as to promote a rate of growth in that infant which approximates to the rate of growth of a breast fed infant of the same age.
14. The use of Claim 12 or 13, wherein the energy density of the composition is between 620 and 640 kcal/litre.
15. The use of any of claims 12 to 14, wherein the protein content of the composition is between 1.4 and 1.7 g/100 kcal.
16. The use of any of Claims 12 to 15, wherein the protein source additionally includes whey protein.
17. The use of any of Claims 12 to 16, wherein the casein: whey ratio is between 30:70 and 70:30.
18. The use of Claim 16 or 17, wherein the whey protein is sweet whey from which the caseino-glycomacropeptide has been removed and the nutritional composition additionally includes free phenylalanine in an amount of up to2.2%, free isoleucine in an amount of up toθ.92%, free tryptophan in an amount of up to 0.34% and free histidine in an amount of up to 0.19%, in each case as a percentage by weight of total protein content.
19. The use of any of Claims 12 to 18, wherein the protein(s) are intact.
20. The use of any of Claims 12 to 19, wherein the carbohydrate source is lactose.
21. The use of any of Claims 12 to 20, wherein the ratio of linoleic acid (C18:2n-6): α-linolenic acid (C18:3n-3)in the lipid source is between 7:1 and 5:1.
22. The use of any of Claims 12 to 21, wherein the nutritional composition further includes a probiotic bacterial strain in an amount of from 106 to 1011 cfu/g of composition (dry weight).
PCT/EP2007/063622 2006-12-15 2007-12-10 Nutritional composition Ceased WO2008071667A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP07857342A EP2096941B1 (en) 2006-12-15 2007-12-10 Nutritional composition for infants
PL07857342T PL2096941T3 (en) 2006-12-15 2007-12-10 Nutritional composition for infants
ES07857342T ES2379737T3 (en) 2006-12-15 2007-12-10 Nutritive composition for babies
BRPI0721087-6A BRPI0721087A2 (en) 2006-12-15 2007-12-10 NUTRITIONAL COMPOSITION
AT07857342T ATE543395T1 (en) 2006-12-15 2007-12-10 NUTRITIONAL COMPOSITION FOR INFANTS
US12/519,043 US9943097B2 (en) 2006-12-15 2007-12-10 Nutritional composition
MX2009006086A MX2009006086A (en) 2006-12-15 2007-12-10 Nutritional composition.
AU2007331578A AU2007331578B2 (en) 2006-12-15 2007-12-10 Nutritional composition
CA002671988A CA2671988A1 (en) 2006-12-15 2007-12-10 Nutritional composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06126282.0 2006-12-15
EP06126282A EP1932437A1 (en) 2006-12-15 2006-12-15 Infant formula

Publications (1)

Publication Number Publication Date
WO2008071667A1 true WO2008071667A1 (en) 2008-06-19

Family

ID=37907402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/063622 Ceased WO2008071667A1 (en) 2006-12-15 2007-12-10 Nutritional composition

Country Status (18)

Country Link
US (1) US9943097B2 (en)
EP (2) EP1932437A1 (en)
CN (1) CN101573049A (en)
AT (1) ATE543395T1 (en)
AU (1) AU2007331578B2 (en)
BR (1) BRPI0721087A2 (en)
CA (1) CA2671988A1 (en)
CL (1) CL2007003650A1 (en)
ES (1) ES2379737T3 (en)
MX (1) MX2009006086A (en)
MY (1) MY158502A (en)
PL (1) PL2096941T3 (en)
PT (1) PT2096941E (en)
RU (1) RU2455857C2 (en)
TW (1) TW200845917A (en)
UA (1) UA96781C2 (en)
WO (1) WO2008071667A1 (en)
ZA (1) ZA200904918B (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070613A2 (en) 2008-12-18 2010-06-24 University College London Baby feeding formula and system
WO2010112429A1 (en) * 2009-04-01 2010-10-07 Nestec S.A. Reduction of risk of obesity
EP2277395A1 (en) * 2009-07-23 2011-01-26 Opus Ingredients B.V. Composition, method for producing it and use thereof
US7998501B2 (en) 2003-02-10 2011-08-16 University College London Newborn infant formulas and feeding methods
EP2583562A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for infants at risk of obesity or diabetes
US8815279B2 (en) 2003-02-10 2014-08-26 University College London Baby feeding formula and system
WO2015078938A1 (en) 2013-11-29 2015-06-04 Nestec S.A. Age-tailored nutritional compositions with a varying protein content
US9474766B2 (en) 2011-12-27 2016-10-25 Abbott Laboratories Use of a reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life
WO2017064309A1 (en) 2015-10-15 2017-04-20 N.V. Nutricia Infant formula with milk fat for promoting healthy growth
WO2017064304A1 (en) 2015-10-15 2017-04-20 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
WO2017194607A1 (en) 2016-05-10 2017-11-16 N.V. Nutricia Fermented infant formula
WO2017194615A1 (en) 2016-05-10 2017-11-16 N.V. Nutricia Fermented infant formula
EP3082463B1 (en) 2013-11-29 2019-05-01 Nestec S.A. Use of nutritional compositions having a low protein amount
US10548869B2 (en) 2010-03-17 2020-02-04 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes
EP3442358B1 (en) 2016-04-11 2021-02-17 Société des Produits Nestlé S.A. Infant nutrition delivering metabolic benefits
US11109603B2 (en) 2011-06-20 2021-09-07 H.J. Heinz Company Brands Llc Probiotic compositions and methods
US11376222B2 (en) 2013-11-01 2022-07-05 N.V. Nutricia Lipid composition for improving body composition during catch-up growth
US11632974B2 (en) 2016-12-09 2023-04-25 N.V. Nutricia Nutritional composition for improving cell membranes

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2452574A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
US9462821B2 (en) 2008-12-08 2016-10-11 Nestec S.A. Modulation of infant fat mass
CA2749254A1 (en) 2009-01-19 2010-07-22 Catherine Mace Nutritional composition for infants
MX2011010454A (en) * 2009-04-03 2012-01-25 Nestec Sa Improvement in promotion of healthy catch-up growth.
EP2404507A1 (en) * 2010-07-08 2012-01-11 Nestec S.A. Array of age-tailored nutritional formula with optimum fat content
WO2012044155A1 (en) * 2010-09-28 2012-04-05 N.V. Nutricia Fat composition for programming immune response
EP2452573A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
WO2012092082A1 (en) * 2010-12-30 2012-07-05 Abbott Laboratories Reduced buffering capacity of a low calorie infant formula
NZ612099A (en) * 2010-12-30 2015-02-27 Abbott Lab Low calorie infant formula with improved physical attributes
MX2013007694A (en) * 2010-12-30 2013-08-15 Abbott Lab Improved tolerance in a low calorie infant formula.
WO2012092083A1 (en) * 2010-12-30 2012-07-05 Abbott Laboratories Improved rate of protein digestion in a low calorie infant formula
EP2514435A1 (en) 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases
CN104302192A (en) * 2011-12-27 2015-01-21 雅培制药有限公司 Reduced calorie infant formulas containing specific whey to casein ratios
RU2670883C2 (en) * 2012-03-12 2018-10-25 Н.В. Нютрисиа Process for the humanization of animal skim milk and products obtained thereby
SE536599C3 (en) 2012-04-10 2017-01-10 Hero Ag Nutritional composition with low calorie and low protein content
US20140170259A1 (en) * 2012-12-14 2014-06-19 Mead Johnson Nutrition Company Nutritional composition for promoting satiety
WO2015041515A1 (en) * 2013-09-19 2015-03-26 N.V. Nutricia Improved process for the humanization of animal skim milk
WO2015078939A1 (en) * 2013-11-29 2015-06-04 Nestec S.A. Devices, systems and methods of assessing the risk of obesity later in life of an infant or a young child
EP3082472A1 (en) * 2013-11-29 2016-10-26 Nestec S.A. Infant nutrition for improvement in insulin sensitivity later in life
AU2014361229A1 (en) 2013-12-12 2016-04-28 Nestec S.A. Synthetic nutritional compositions especially adapted for male and female infants and young children
WO2015095570A2 (en) * 2013-12-19 2015-06-25 Abbott Laboratories Nutritional composition comprising hydrolyzed protein
BR112016014700B1 (en) * 2014-01-10 2020-11-10 Société Des Produits Nestlé S.A uses of vitamin b6, and maternal food composition
CN114469959A (en) * 2014-03-21 2022-05-13 雀巢产品有限公司 Administering vitamin B2 to mothers prevents increased offspring obesity, overweight or obesity
WO2015178762A1 (en) * 2014-05-19 2015-11-26 N.V. Nutricia Enteral formulations for preterm infants comprising optimised phenylalanine intake levels
WO2015178761A1 (en) * 2014-05-19 2015-11-26 N.V. Nutricia Formulas comprising optimised amino acid profiles
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
JOP20190146A1 (en) 2016-12-19 2019-06-18 Axcella Health Inc Amino acid compositions and methods for the treatment of liver diseases
JOP20200033A1 (en) 2017-08-14 2020-02-13 Axcella Health Inc Amino acid compositions for the treatment of liver disease
WO2019246225A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
WO2021110916A1 (en) * 2019-12-05 2021-06-10 N.V. Nutricia Infant formula with special lipid architecture for improving postnatal growth of infants born to overweight and obese mothers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124237A1 (en) * 2001-12-21 2003-07-03 Wyeth Infant formula compositions comprising increased amounts of alpha-lactalbumin
WO2004112508A1 (en) * 2003-06-23 2004-12-29 Nestec S.A. Infant or follow-on formula
WO2006057551A1 (en) * 2004-11-26 2006-06-01 N.V. Nutricia Infant nutrition with protease inhibitor
WO2006069918A1 (en) * 2004-12-27 2006-07-06 Nestec S.A. Use of infant formula with reduced protein content
WO2007004878A2 (en) * 2005-07-01 2007-01-11 N.V. Nutricia Infant nutrition with hydrolised proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0880902A1 (en) 1997-05-27 1998-12-02 Nestlé Produkte AG Process for treating a raw whey material
EP0951842B1 (en) * 1999-01-20 2002-12-04 N.V. Nutricia Infant formula
GB9923048D0 (en) * 1999-09-29 1999-12-01 Nestle Sa Composition comprising casein protein and whey protein
BRPI0407220A (en) * 2003-02-10 2006-01-31 Univ London Baby Feeding Formula and Baby Feeding Formula Container

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124237A1 (en) * 2001-12-21 2003-07-03 Wyeth Infant formula compositions comprising increased amounts of alpha-lactalbumin
WO2004112508A1 (en) * 2003-06-23 2004-12-29 Nestec S.A. Infant or follow-on formula
WO2006057551A1 (en) * 2004-11-26 2006-06-01 N.V. Nutricia Infant nutrition with protease inhibitor
WO2006069918A1 (en) * 2004-12-27 2006-07-06 Nestec S.A. Use of infant formula with reduced protein content
WO2007004878A2 (en) * 2005-07-01 2007-01-11 N.V. Nutricia Infant nutrition with hydrolised proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEMMELMAIR H, VON ROSEN J, KOLETZKO B: "Long-term consequences of early nutrition", EARLY HUMAN DEVELOPMENT, vol. 82, no. 8, August 2006 (2006-08-01), pages 567 - 574, XP002429678 *
FOMON SJ, ZIEGLER EE, NELSON SE, FRANTZ JA: "What is the safe protein-energy ratio for infant formulas?", AMERICAL JOURNAL OF CLINICAL NUTRITION, vol. 62, 1995, pages 358 - 363, XP009082308 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703173B2 (en) 2003-02-10 2014-04-22 University College London Newborn infant formulas and feeding methods
US8815279B2 (en) 2003-02-10 2014-08-26 University College London Baby feeding formula and system
US7998501B2 (en) 2003-02-10 2011-08-16 University College London Newborn infant formulas and feeding methods
WO2010070613A2 (en) 2008-12-18 2010-06-24 University College London Baby feeding formula and system
WO2010070613A3 (en) * 2008-12-18 2010-12-23 University College London Baby feeding formula and system
RU2559646C2 (en) * 2009-04-01 2015-08-10 Нестек С.А. Adiposity risk reduction
US9480670B2 (en) 2009-04-01 2016-11-01 Nestec S.A. Reduction of risk of obesity
WO2010112429A1 (en) * 2009-04-01 2010-10-07 Nestec S.A. Reduction of risk of obesity
CN102368913A (en) * 2009-04-01 2012-03-07 雀巢产品技术援助有限公司 Reduction of risk of obesity
US9480671B2 (en) 2009-04-01 2016-11-01 Nestec S.A. Reduction of risk of obesity
AU2010230362B2 (en) * 2009-04-01 2015-01-15 Société des Produits Nestlé S.A. Reduction of risk of obesity
EP2277395A1 (en) * 2009-07-23 2011-01-26 Opus Ingredients B.V. Composition, method for producing it and use thereof
US10548869B2 (en) 2010-03-17 2020-02-04 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes
US11109603B2 (en) 2011-06-20 2021-09-07 H.J. Heinz Company Brands Llc Probiotic compositions and methods
US11771102B2 (en) 2011-06-20 2023-10-03 H.J. Heinz Company Brands Llc Probiotic compositions and methods
EP2583562A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for infants at risk of obesity or diabetes
WO2013057233A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Use of whey protein micelles for infants at risk of obesity or diabetes
EP2779846B1 (en) 2011-10-21 2017-09-06 Nestec S.A. Use of whey protein micelles for infants at risk of obesity or diabetes
US9474766B2 (en) 2011-12-27 2016-10-25 Abbott Laboratories Use of a reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life
US11376222B2 (en) 2013-11-01 2022-07-05 N.V. Nutricia Lipid composition for improving body composition during catch-up growth
US20170000181A1 (en) * 2013-11-29 2017-01-05 Nestec S.A. Age-tailored nutritional compositions with a varying protein content
WO2015078938A1 (en) 2013-11-29 2015-06-04 Nestec S.A. Age-tailored nutritional compositions with a varying protein content
EP3082463B1 (en) 2013-11-29 2019-05-01 Nestec S.A. Use of nutritional compositions having a low protein amount
EP3073844B1 (en) 2013-11-29 2020-01-22 Société des Produits Nestlé S.A. Age-tailored nutritional compositions with a varying protein content
WO2017064304A1 (en) 2015-10-15 2017-04-20 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
EP3574771A1 (en) 2015-10-15 2019-12-04 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
US11389403B2 (en) 2015-10-15 2022-07-19 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
EP4190174A1 (en) 2015-10-15 2023-06-07 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
WO2017064309A1 (en) 2015-10-15 2017-04-20 N.V. Nutricia Infant formula with milk fat for promoting healthy growth
EP3442358B1 (en) 2016-04-11 2021-02-17 Société des Produits Nestlé S.A. Infant nutrition delivering metabolic benefits
US11388922B2 (en) 2016-04-11 2022-07-19 Societe Des Produits Nestle S.A. Infant nutrition delivering metabolic benefits
US12004545B2 (en) 2016-04-11 2024-06-11 Societe Des Produits Nestle S.A. Infant nutrition delivering metabolic benefits
EP3841892A1 (en) 2016-05-10 2021-06-30 N.V. Nutricia Fermented infant formula
WO2017194615A1 (en) 2016-05-10 2017-11-16 N.V. Nutricia Fermented infant formula
WO2017194607A1 (en) 2016-05-10 2017-11-16 N.V. Nutricia Fermented infant formula
US11632974B2 (en) 2016-12-09 2023-04-25 N.V. Nutricia Nutritional composition for improving cell membranes

Also Published As

Publication number Publication date
BRPI0721087A2 (en) 2014-02-25
EP2096941A1 (en) 2009-09-09
CL2007003650A1 (en) 2009-03-27
EP2096941B1 (en) 2012-02-01
US9943097B2 (en) 2018-04-17
MY158502A (en) 2016-10-14
PL2096941T3 (en) 2012-07-31
RU2009127103A (en) 2011-01-20
MX2009006086A (en) 2009-07-02
ES2379737T3 (en) 2012-05-03
TW200845917A (en) 2008-12-01
PT2096941E (en) 2012-04-11
EP1932437A1 (en) 2008-06-18
UA96781C2 (en) 2011-12-12
CA2671988A1 (en) 2008-06-19
AU2007331578A1 (en) 2008-06-19
CN101573049A (en) 2009-11-04
ATE543395T1 (en) 2012-02-15
RU2455857C2 (en) 2012-07-20
US20100092610A1 (en) 2010-04-15
ZA200904918B (en) 2010-09-29
AU2007331578B2 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
AU2007331578B2 (en) Nutritional composition
EP1220620B1 (en) Composition comprising casein protein and whey protein
WO2006069918A1 (en) Use of infant formula with reduced protein content
EP2413718B1 (en) Use of arachidonic acid for the reduction of the risk of insulin resistance later in life
AU2009306497B2 (en) Nutritional composition with anti-regurgitation properties
WO2019104390A1 (en) Milk substitute compositions
WO2010066569A1 (en) Modulation of infant fat mass
HK1122700A (en) Infant formula
MX2008009805A (en) Nutritional composition for low birth weight infants

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780048795.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07857342

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007857342

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2671988

Country of ref document: CA

Ref document number: 3771/DELNP/2009

Country of ref document: IN

Ref document number: MX/A/2009/006086

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12519043

Country of ref document: US

Ref document number: 2007331578

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12009501232

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2007331578

Country of ref document: AU

Date of ref document: 20071210

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009127103

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0721087

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090615